Compare CCIF & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCIF | CLNN |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 120.6M |
| IPO Year | N/A | N/A |
| Metric | CCIF | CLNN |
|---|---|---|
| Price | $5.20 | $5.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 76.9K | ★ 305.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.43 | $2.28 |
| 52 Week High | $10.16 | $13.50 |
| Indicator | CCIF | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 32.08 |
| Support Level | $5.15 | $8.90 |
| Resistance Level | $5.33 | $9.92 |
| Average True Range (ATR) | 0.13 | 1.03 |
| MACD | 0.03 | -0.40 |
| Stochastic Oscillator | 73.44 | 2.12 |
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.